Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Outlook Therapeutics Inc’s stock clocked out at $1.85, up 4.52% from its previous closing price of $1.77. In other words, the price has increased by $4.52 from its previous closing price. On the day, 0.92 million shares were traded.
Ratios:
To gain a deeper understanding of OTLK’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.57 and its Current Ratio is at 0.72.
On March 27, 2024, BTIG Research Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $50.
Chardan Capital Markets Upgraded its Neutral to Buy on February 15, 2024, while the target price for the stock was maintained at $3.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 26 ’24 when KENYON LAWRENCE A bought 5,000 shares for $5.69 per share. The transaction valued at 28,446 led to the insider holds 5,946 shares of the business.
Stock Price History:
Over the past 52 weeks, OTLK has reached a high of $9.25, while it has fallen to a 52-week low of $0.87. The 50-Day Moving Average of the stock is 23.28%, while the 200-Day Moving Average is calculated to be -43.35%.
Shares Statistics:
A total of 32.91M shares are outstanding, with a floating share count of 21.22M. Insiders hold about 50.49% of the company’s shares, while institutions hold 16.68% stake in the company.
Earnings Estimates
A comprehensive evaluation of Outlook Therapeutics Inc (OTLK) is underway, with the input of 3.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.32, with high estimates of -$0.13 and low estimates of -$0.51.
Analysts are recommending an EPS of between -$1.4 and -$2.52 for the fiscal current year, implying an average EPS of -$2.08. EPS for the following year is -$1.29, with 3.0 analysts recommending between -$0.95 and -$1.77.
Revenue Estimates
For the next quarter, 4 analysts are estimating revenue of $6.76M. There is a high estimate of $8.7M for the next quarter, whereas the lowest estimate is $4M.
Based on 5 analysts’ estimates, the company’s revenue will be $34.93M in the next fiscal year. The high estimate is $50.95M and the low estimate is $17.1M.
